While regulators begin to address nano-based drugs, industry should get its risk data ready.
David W. Hobson
Advertisement
David W. Hobson is chief scientific officer for nanoTox Inc., tel. 877.804.2828.
Articles by David W. Hobson
Advertisement
Latest Updated Articles
Opportunities and Challenges in Pharmaceutical NanotechnologyPublished: July 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AAPS PharmSci 360 2025: Trends in Bioanalysis
2
PharmTech Weekly News Roundup – Week of November 3, 2025
3
AAPS PharmSci 360 2025: The Role of LC–MS in Bioanalysis
4
How AI, Machine Learning, and Large Language Models Enhance Bioanalysis
5
